Paysign posts investor deck on transaction, workflow platform spanning healthcare and financial rails

• Paysign outlined a two-engine platform spanning plasma donor payments and pharma patient affordability, supported by a shared transaction and workflow infrastructure.
• FY 2025 revenue USD 82 million, up 40.5% year over year; adjusted EBITDA USD 19.9 million, up 107.3%; gross margin 59.4%.
• 2026 guidance calls for revenue USD 106.5 million to USD 110.5 million; adjusted EBITDA USD 30 million to USD 33 million; implied margin 27% to 31%.
• Patient affordability revenue over the trailing 12 months rose 116.9% to USD 40.9 million; 141 active pharma programs; revenue per program USD 116,122 in Q1 2026.
• Plasma business cited about 45.5% US market share; 554 facilities served; 8.4 million cardholders; bank debt at USD 0.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.